Alexandria Real Estate Equities, Inc.’s (ARE) portfolio of high-quality, niche assets — life science, technology and agtech properties — in strategic markets is well-poised to benefit from solid demand for life science assets due to the increasing need for drug research and innovation. However, a huge development outlay raises the risks of cost overruns and lease-up concerns amid macroeconomic uncertainty and a high interest rate environment. What’s Aiding ARE? Alexandria owns Class A/A+ properties in the A ...